Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.

[1]  A. Italiano,et al.  Phase-II trials in osteosarcoma recurrences: A systematic review of past experience. , 2017, European journal of cancer.

[2]  D. Bota,et al.  Systemic cisplatin exposure during infancy and adolescence causes impaired cognitive function in adulthood , 2017, Behavioural Brain Research.

[3]  J. Meza,et al.  Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. am Zehnhoff-Dinnesen,et al.  Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. , 2016, European journal of cancer.

[5]  Katherine E Henson,et al.  Cardiac Mortality Among 200 000 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age , 2016, Circulation.

[6]  K. S. Hall,et al.  Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial , 2016, The Lancet. Oncology.

[7]  H. Berg,et al.  Different infusion durations for preventing platinum‐induced hearing loss in children with cancer , 2016 .

[8]  J. Blay,et al.  Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[9]  L. Kremer,et al.  Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. , 2016, The Cochrane database of systematic reviews.

[10]  Y. T. Cheung,et al.  Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. , 2016, JAMA oncology.

[11]  E. Soliman,et al.  Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy , 2016, Annals of Internal Medicine.

[12]  P. Meltzer,et al.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Sydes,et al.  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. S. Hall,et al.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  S. Wild,et al.  Subsequent hospitalisation experience of 5-year survivors of childhood, adolescent, and young adult cancer in Scotland: a population based, retrospective cohort study , 2013, British Journal of Cancer.

[16]  K. Ness,et al.  Pilot study of vascular health in survivors of osteosarcoma , 2013, Pediatric blood & cancer.

[17]  David M. Thomas,et al.  Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Gelderblom,et al.  Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? , 2011, European Journal of Cancer.

[19]  G. Leverger,et al.  Long-term evaluation of Ifosfamide-related nephrotoxicity in children. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Vanel,et al.  SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. , 2007, European journal of cancer.

[22]  E. Kleinerman,et al.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Bielack,et al.  Cisplatin-Induced Ototoxicity in Osteosarcoma Patients: A Report from the Late Effects Surveillance System , 2005, Cancer investigation.

[24]  J. Cayuela,et al.  Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Nitz,et al.  Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. , 2013, Oncology letters.

[26]  J. Stockman.  Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort , 2011 .